公开(公告)号：US10265279B2

公开(公告)日：2019-04-23

申请号：US15458640

申请日：2017-03-14

Applicant: ORYZON GENOMICS, S.A.

Inventor： Mark D. Demario ,  Tamara Maes ,  William E. Pierceall ,  Fiona Mack ,  Serena Lunardi

IPC: A61K31/135 ,  A61K31/55 ,  A61K31/551 ,  A61K31/4402 ,  A61K31/47 ,  A61K31/52 ,  A61K31/404 ,  A61K31/635 ,  A61K31/167 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/4745 ,  A61K31/12 ,  A61K31/19 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4045 ,  A61K31/475 ,  A61K31/495 ,  A61K31/519 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7068

Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).